Recombinant IL13 (Lebrikizumab Biosimilar) antibody
This Mammalian Cells Monoclonal antibody specifically detects IL13 (Lebrikizumab Biosimilar) in ELISA. It exhibits reactivity toward Human.
Catalog No. ABIN7487944
$336.06
Plus shipping costs $50.00
Shipping to:
United States
Delivery in 7 to 10 Business Days
Quick Overview for Recombinant IL13 (Lebrikizumab Biosimilar) antibody (ABIN7487944)
Target
IL13 (Lebrikizumab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
Mammalian Cells
Clonality
Monoclonal
Conjugate
This IL13 (Lebrikizumab Biosimilar) antibody is un-conjugated
Application
ELISA
Grade
Research Grade
-
-
Expression System
- Mammalian cells
-
Purpose
- Lebrikizumab Biosimilar - Anti-IL13 mAb
-
Characteristics
- Antibody Type: IgG4-kappa
-
Purification
- Recombinant antibody expressed in mammalien cells and purified.
-
Isotype
- IgG4 kappa
-
-
-
-
Restrictions
- For Research Use only
-
-
-
Buffer
- PBS pH 7.5
-
Storage
- -80 °C
-
Storage Comment
- store at -80°C
-
-
- IL13 (Lebrikizumab Biosimilar)
-
Target Type
- Biosimilar
-
Background
-
MILR1444A,PRO301444
Lebrikizumab is a humanized monoclonal antibody targeting IL13, it is an experimental immunosuppressive drug for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids. -
CAS-No
- 953400-68-5
Target
-
You are here:
